Dosimetric analysis of the short-ranged particle emitter161 tb for radionuclide therapy of metastatic prostate cancer

Peter Bernhardt*, Johanna Svensson, Jens Hemmingsson, Nicholas P. van der Meulen, Jan Rijn Zeevaart, Mark W. Konijnenberg, Cristina Müller, Jon Kindblom

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)
29 Downloads (Pure)


The aim of this study was to analyze the required absorbed doses to detectable metastases (Dreq ) when using radionuclides with prostate specific membrane antigen (PSMA)-targeting radioligands to achieve a high probability for metastatic control. The Monte Carlo based analysis was performed for the clinically-used radionuclides yttrium-90, iodine-131, lutetium-177, and actinium-225, and the newly-proposed low-energy electron emitter terbium-161. It was demonstrated that metastatic formation rate highly influenced the metastatic distribution. Lower values generated few large detectable metastases, as in the case with oligo metastases, while high values generated a distribution of multiple small detectable metastases, as observed in patients with diffused visualized metastases. With equal number of detectable metastases, the total metastatic volume burden was 4–6 times higher in the oligo metastatic scenario compared to the diffusely visualized scenario. The Dreq was around 30% higher for the situations with 20 detectable metastases compared to one detectable metastasis. The Dreq for iodine-131 and yttrium-90 was high (920–3300 Gy). The Dreq for lutetium-177 was between 560 and 780 Gy and considerably lower Dreq were obtained for actinium-225 and terbium-161, with 240–330 Gy and 210–280 Gy, respectively. In conclusion, the simulations demonstrated that terbium-161 has the potential for being a more effective targeted radionuclide therapy for metastases using PSMA ligands.

Original languageEnglish
Article number2011
Issue number9
Publication statusPublished - 22 Apr 2021

Bibliographical note

Funding: This work was supported by the Swedish Cancer Society, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement, the Swedish Research Council, the Swiss National Science Foundation (IZLIZ3_156800), and the NET Research Foundation Petersen Investigator Award 2018.

Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Dosimetric analysis of the short-ranged particle emitter161 tb for radionuclide therapy of metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this